T1	intervention 79 105	paclitaxel followed by FEC
T2	control 132 173	paclitaxel and everolimus followed by FEC
T3	eligibility 177 226	women with triple receptor-negative breast cancer
T4	intervention 619 624	T-FEC
T5	intervention 686 700	5-fluorouracil
T6	intervention 714 724	epirubicin
T7	intervention 742 758	cyclophosphamide
T8	control 809 815	TR-FEC
T9	control 848 858	everolimus
T10	control 901 904	FEC
T11	outcome-Measure 1107 1150	12-week clinical response rate (12-week RR)
T12	outcome-Measure 1152 1188	pathological complete response (pCR)
T13	outcome-Measure 1194 1202	toxicity
T14	No-of-participants 1204 1213	Sixty-two
T15	No-of-participants 1244 1246	50
T16	intervention-participants 1264 1266	27
T17	control-participants 1287 1289	23
T18	average-age 1322 1338	48 (range 31-75)
T19	outcome 1350 1384	downregulation of the mTOR pathway
T20	outcome 1412 1440	Twelve-week RR by ultrasound
T21	intervention-value 1446 1451	29.6%
T22	control-value 1459 1464	47.8%
T23	outcome 1483 1486	pCR
T24	intervention-value 1492 1497	25.9%
T25	control-value 1505 1510	30.4%
T26	adverse-effect 1691 1697	anemia
T27	adverse-effect 1699 1710	neutropenia
T28	adverse-effect 1712 1729	rash/desquamation
T29	adverse-effect 1735 1743	vomiting
T30	control-value 1768 1771	one
T31	outcome 1780 1799	grade 3 pneumonitis
T32	outcome 1819 1842	No grade 3/4 stomatitis
